1. Pfizer may request emergency authorization for COVID-19 vaccine as soon as third week of November  ARIRANG NEWS
  2. Pfizer sees emergency use filing for Covid-19 vaccine after U.S. election  CNBC
  3. Pfizer COVID-19 vaccine not ready before Election Day  Reuters
  4. Pfizer and BioNTech Vaccine Could Be Ready By the End of November. We’re All Winners.  Barron's
  5. What’s Happening With Moderna Stock?  Forbes
  6. View Full coverage on Google News

Trump, Biden square off in dueling town halls, U.S. Covid-19 cases reach a third peak, date set for committee vote on Barrett nomination, and other news to start your day. Trump, Biden square off in dueling town halls, U.S. Covid-19 cases reach a third peak, date set for committee vote on Barrett nomination, and other news to start your day.

Pfizer and BioNTech Vaccine Could Be Ready By the End of November. We’re All Winners. | Barron's

An open letter from the frontrunner COVID-19 vaccine producer published Friday ends any expectations a vaccine might be available before Election Day.An open letter from the frontrunner COVID-19 vaccine producer published Friday ends any expectations a vaccine might be available before Election Day.

Pfizer CEO letter makes Thanksgiving earliest date for COVID-19 vaccine

Record high infection rates in the Midwest are driving the latest surge in coronavirus cases that have exceeded some daily totals reported over the summer.Record high infection rates in the Midwest are driving the latest surge in coronavirus cases that have exceeded some daily totals reported over the summer.

Outbreaks in the Midwest driving surge in COVID-19 cases

The race for a COVID-19 vaccine is heating up as cases rise worldwide. The chair of the U.K. Vaccine Taskforce says there's a slim chance a vaccine may be ready by Christmas. CBS News foreign correspondent Charlie D'Agata reports.The race for a COVID-19 vaccine is heating up as cases rise worldwide. The chair of the U.K. Vaccine Taskforce says there's a slim chance a vaccine may be ready by Christmas. CBS News foreign correspondent Charlie D'Agata reports.

Race to find a COVID-19 vaccine as cases rise worldwide - CBS News

Moderna stock has rallied by almost 15% over the past month, as the company continues with its phase 3 clinical trials, with late-stage clinical data likely available in the next month or so. Moderna says that it could file for emergency use authorization from the U.S. FDA around November 25...Moderna stock has rallied by almost 15% over the past month, as the company continues with its phase 3 clinical trials, with late-stage clinical data likely available in the next month or so. Moderna says that it could file for emergency use authorization from the U.S. FDA around November 25...

What’s Happening With Moderna Stock?

The drug maker’s CEO said Pfizer plans to apply for emergency use authorization by late November.The drug maker’s CEO said Pfizer plans to apply for emergency use authorization by late November.

Pfizer won't be seeking emergency approval for coronavirus vaccine before election | TheHill

The drug maker’s CEO said Pfizer plans to apply for emergency use authorization by late November.The drug maker’s CEO said Pfizer plans to apply for emergency use authorization by late November.

Pfizer won't be seeking emergency approval for coronavirus vaccine before election | TheHill

The mRNA coronavirus vaccine being developed by Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) is unlikely to become available ...The mRNA coronavirus vaccine being developed by Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) is unlikely to become available under emergency use...

Pfizer, Inc. (NYSE:PFE), (BNTX) - Pfizer CEO: Emergency Use Application For Coronavirus Vaccine Could Come In Late November | Benzinga

But that makes it unlikely a vaccine will be available before the US election which President Trump has promised.But that makes it unlikely a vaccine will be available before the US election which President Trump has promised.

search

Pfizer CEO says it can't seek emergency authorization of its COVID-19 vaccine before the third week of November — and that's if everything goes wellPfizer CEO says it can't seek emergency authorization of its COVID-19 vaccine before the third week of November — and that's if everything goes well

Pfizer says earliest U.S. filing for COVID-19 vaccine would be late November

Chinese Covid-19 vaccine candidate -- BBIBP-CorV -- that is expected to completely inactivate the SARS-CoV-2 virus, is safe and elicits an antibody response, a study published in The Lancet has found.Chinese Covid-19 vaccine candidate -- BBIBP-CorV -- that is expected to completely inactivate the SARS-CoV-2 virus, is safe and elicits an antibody response, a study published in The Lancet has found.

China's Covid-19 vax is safe, prompts antibody response: Lancet | greatandhra.com

Vaccine developers must provide two months of safety data on half of the trial participants following the final dose of the vaccine.Vaccine developers must provide two months of safety data on half of the trial participants following the final dose of the vaccine.

A $60 double-dose experimental coronavirus vaccine is being made available to some residents in an eastern Chinese city, health officials have said, the first details of a mass rollout for an as-yet unproven vaccine. Officials in Jiaxing city said Thursday residents aged between 18 and 59 with "urgent needs" can seek consultations at clinics for a Sinovac Biotech vaccine thatA $60 double-dose experimental coronavirus vaccine is being made available to some residents in an eastern Chinese city, health officials have said, the first details of a mass rollout for an as-yet

$60 experimental coronavirus vaccine rolled out in eastern Chinese city | Deccan Herald

Pfizer CEO Albert Bourla recently suggested the company would know whether its BioNTech-shared COVID-19 vaccine works by October. Criticism ensued. Now finding himself alone in the biopharma world with that bullish estimate, the Big Pharma chief is changing his tone.Pfizer CEO Albert Bourla recently suggested the company would know whether its BioNTech-shared COVID-19 vaccine works by October. Criticism ensued. Now finding himself alone in the biopharma world with that bullish estimate, the Big Pharma chief is changing his tone.

Pfizer CEO, facing pushback, shifts COVID-19 vaccine timeline to late November | FiercePharma

News, analysis and comment from the Financial Times, the worldʼs leading global business publication

Subscribe to read | Financial Times

Covid-19 vaccine trials are advancing fast – but anti-vaccine sentiment is growing tooCovid-19 vaccine trials are advancing fast – but anti-vaccine sentiment is growing too

‘Stick your vaccine up your arse’ – the Covid-19 vaccine, the science and the sceptics

India News: As the world prepares for a vaccine against Covid-19, India has started identifying around 30 crore priority beneficiaries, including high-risk populIndia News: As the world prepares for a vaccine against Covid-19, India has started identifying around 30 crore priority beneficiaries, including high-risk popul

Covid-19: Govt identifying 30 crore who will get vaccine on priority | India News - Times of India

Bloomberg - Are you a robot?

A previous clinical trial reported similar results for a different vaccine that is also based on inactivated whole SARS-CoV-2 virus, but in that study the vaccine was only tested in people aged under 60 years. The latest study, published in The Lancet Infectious Diseases journal, included participants aged between 18 and 80 years, and found that antibody responses were induced in all recipients.A previous clinical trial reported similar results for a different vaccine that is also based on inactivated whole SARS-CoV-2 virus, but in that study the vaccine was only tested in people aged under 60 years. The latest study, published in The Lancet Infectious Diseases journal, included participants aged between 18 and 80 years, and found that antibody responses were induced in all recipients.

Chinese COVID-19 vaccine candidate shows promise in human trial: Study | Health

WASHINGTON" The US pharmaceutical giant Pfizer expects to file for emergency use authorisation for its Covid-19 vaccine in late November, around two weeks after the Nov 3 US presidential election, it said on Friday.WASHINGTON" The US pharmaceutical giant Pfizer expects to file for emergency use authorisation for its Covid-19 vaccine in late November, around two weeks after the Nov 3 US presidential election, it said on Friday.

Pfizer to seek vaccine approval in November

The head of the UK Vaccine Taskforce says it would not mean that life would get back to normal straight away.The head of the UK Vaccine Taskforce says it would not mean that life would get back to normal straight away.

sign-in

Having struggled to contain the spread of the coronavirus, the country has put all its chips on securing access to an effective vaccine.Having struggled to contain the spread of the coronavirus, the country has put all its chips on securing access to an effective vaccine.

Indonesia Secures Access to Promising British COVID-19 Vaccine – The Diplomat

The CDC put out a central playbook for how to distribute the shots. But how states will address these guidelines is anything but uniform.The CDC put out a central playbook for how to distribute the shots. But how states will address these guidelines is anything but uniform.

In the US, 50 States Could Mean 50 Vaccine Rollout Strategies | WIRED

US pharmaceutical giant Pfizer expects to file for emergency use authorization for its Covid-19 vaccine in late November, around two weeks after the November 3 US presidential election, it said Frida…US pharmaceutical giant Pfizer expects to file for emergency use authorization for its Covid-19 vaccine in late November, around two weeks after the November 3 US presidential election, it said Frida…

Pfizer plans to seek authorization for Covid-19 vaccine next month

A Chinese drug developer is offering an experimental coronavirus vaccine to students going abroad in a strategy health experts say raises safety and ethical concerns. China National Biotech Group has two vaccine candidates out of five from Chinese developers that are in the final stages of clinicalA Chinese drug developer is offering an experimental coronavirus vaccine to students going abroad in a strategy health experts say raises safety and ethical concerns. China National Biotech Group has two vaccine candidates out of five from Chinese developers that are in the final stages of clinical

Chinese company offers coronavirus vaccine to students

Pfizer Chairman and CEO Albert Bourla said in a public statement Friday that the company won't have data showing that the vaccine is safe before the third week of November at the earliest.Pfizer Chairman and CEO Albert Bourla said in a public statement Friday that the company won't have data showing that the vaccine is safe before the third week of November at the earliest.

Pfizer COVID-19 Vaccine Delayed Until At Least Late November : Coronavirus Live Updates : NPR

Some states, including Wisconsin, are experiencing a strain on hospitals, as Pfizer announced today that it won't likely be able to apply for emergency use for its vaccine until a few weeks after the election.Some states, including Wisconsin, are experiencing a strain on hospitals, as Pfizer announced today that it won't likely be able to apply for emergency use for its vaccine until a few weeks after the election.

US surpasses 8 million COVID-19 cases | CIDRAP

According to the recent World Bank report, an estimated 1 billion students in developing nations may be out of school. CoronavirusA World Bank report says about 1 billion students in developing countries may be out of school due to the looming second wave of COVID-19.

1 billion students in developing nations may be out of school due to second wave of COVID-19 - World Bank | Nairametrics

Health authorities in Jiaxing, East China’s Zhejiang Province, announced on Thursday that the city has been administering China’s homegrown inactivated COVID-19 vaccines among high-risk groups and would gradually offer it to ordinary citizens for urgent use.

Eastern Chinese cities to offer ordinary citizens COVID-19 vaccines - Global Times

NEW: Pfizer says it hopes to seek authorisation for its COVID-19 vaccine in mid-NovemberNEW: Pfizer says it hopes to seek authorisation for its COVID-19 vaccine in mid-November

Pfizer says it hopes to seek authorisation for its COVID-19 vaccine in mid-November | Euronews

Pfizer (PFE) stock is on the higher after the company announced it could submit an Emergency Use Authorization application by as soon as the end of November

Blue-Chip Drugmaker Moves Higher on Vaccine Announcement

The pharmaceutical giant just laid out a timetable for when it expects to be able to meet the FDA's EUA application requirements for BNT162.The pharmaceutical giant just laid out a timetable for when it expects to be able to meet the FDA's EUA application requirements for BNT162.

Pfizer Hopes to Apply for Coronavirus Vaccine Emegency Use Authorization in November | The Motley Fool

A COVID-19 vaccine could arrive before the end of 2020, based on a timeline Pfizer's CEO laid out. In an open letter posted to Pfizer's website, CEO Albert Bourla wrote, "Assuming positive data, Pfizer will apply for emergency authorization use in the U. S. soon after the safety milestone is achieved in the third week of November. " COVID-19: Find the latest news on the outbreak in West Michigan by visiting the News Channel 3 coronavirus page.A COVID-19 vaccine could arrive before the end of 2020, based on a timeline Pfizer's CEO laid out. In an open letter posted to Pfizer's website, CEO Albert Bourla wrote, "Assuming positive data, Pfizer will apply for emergency authorization use in the U. S. soon after the safety milestone is achieved in the third week of November. " COVID-19: Find the latest news on the outbreak in West Michigan by visiting the News Channel 3 coronavirus page.

Pfizer could seek November vaccine authorization | WWMT

Pfizer could seek November vaccine authorization

Dozens of companies, from biotech start-ups to Big Pharma, are racing to develop a safe and effective COVID-19 vaccine, because the world needs it and for the potential pay day.

The race for a COVID-19 vaccine heats up

The companies are testing their vaccines against a placebo in healthy volunteers to see if the rate of COVID-19 infection among those who got the vaccineThe companies are testing their vaccines against a placebo in healthy volunteers to see if the rate of COVID-19 infection among those who got the vaccine

Where are we in the COVID-19 vaccine race?

NewZimbabwe.com – The Zimbabwe News You Trust is Zimbabwe’s leading online newspaper and published by New Zimbabwe Media Ltd. The platform brings you the latest breaking News, Business, Showbiz, Sports, Diaspora and gives you everything you’ve come to expect and love.Spread This NewsMailOnLine Hopes of getting a Covid-19 vaccine were boosted again today after an experimental Chinese jab was found to be safe and produce an immune response. Every volunteer given a double-dose of state-owned firm Sinopharm’s vaccine made antibodies against SARS-CoV-2, the coronavirus that causes Covid-19. In theory, this would protect them from catching

More Covid-19 vaccine hopes as scientists say experimental Chinese jab is safe - NewZimbabwe.com

BEIJING, Oct 16 — One of China’s front-running coronavirus vaccine candidates was shown to be safe and triggered immune responses in a combined early and mid-stage test in humans, researchers said. The potential vaccine, dubbed BBIBP-CorV, is being developed by the Beijing Institute of...BEIJING, Oct 16 — One of China’s front-running coronavirus vaccine candidates was shown to be safe and triggered immune responses in a combined early and mid-stage test in humans, researchers said. The potential vaccine, dubbed BBIBP-CorV, is being developed by the Beijing Institute of...

Study: Covid-19 vaccine candidate from China’s CNBG shows promise in human test | Life | Malay Mail

Results of BBIBP-CorV vaccine currently underway in UAE will provide information whether it is safe and efficacious.Results of BBIBP-CorV vaccine currently underway in UAE will provide information whether it is safe and efficacious.

Chinese Covid-19 vaccine found to be safe on humans: Study - News | Khaleej Times

COVID-19 vaccine, and China-Africa health cooperation, are their focus.

50 African diplomats visit Chinese coronavirus vaccine maker - CGTN

Investors have been closely following every twist and turn in the global race to develop a coronavirus vaccine. Yesterday it was Pfizer’s turn in the spotlight.The American pharmaceuticals companyInvestors have been closely following every twist and turn in the global race to develop a coronavirus vaccine. Yesterday it was Pfizer’s turn in the spotlight.The American pharmaceuticals company